60 Degrees Pharmaceuticals, Inc. (SXTP): Capital Expenditures
$139.9K
Year ended 2025-12-31
$119.9K
Trailing 12 months to 2026-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $139.9K | +34.8% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $103.8K | +80.1% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $57.6K | n/a | 2025-03-27, From 2023-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $139.9K | +34.8% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $71.0K | +20.3% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $385.3K | -32.8% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $4.0K | -97.2% |
| Bespoke Extracts, Inc. (BSPK) | 2024-12-31 | $600.0K | n/a |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2025-03-31 | $2.0K | -71.4% |
| Rallybio Corp (RLYB) | 2024-12-31 | $0 | -100.0% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $245.0K | -62.6% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $28.5K | +762.8% |
Compare SXTP, STTK, DARE, RFL side by side · Screen every company in Pharmaceutical Preparations ↗